What did Leerink Partners say in its March 12, 2026 note?

Leerink Partners reiterated an **Outperform** rating for Tenaya on **March 12, 2026**, citing that the company “remains on track to share interim data.” The note did not include a new TNYA price target or valuation revision.

Did William Blair change its view on TNYA on March 12, 2026?

William Blair maintained an **Outperform** rating on **March 12, 2026**, noting “increasing momentum” entering 2026. The firm did not publish a new TNYA price target in the reiteration.

How should investors interpret the maintained TNYA analyst rating?

A maintained Outperform rating means analysts expect TNYA to outpace peers, driven by clinical catalysts and execution. Investors should combine the TNYA analyst rating with upcoming data milestones and cash runway before adjusting positions.

Where can I read the original analyst notes?

The analyst notes were distributed via StreetInsider on **March 12, 2026**. See the Leerink and William Blair notices on StreetInsider for the full commentary and timestamps.

Analyst Ratings

Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026

ByDanny Kontos March 13, 2026March 13, 2026

On March 12, 2026, Leerink Partners and William Blair each maintained an Outperform rating on Tenaya Therapeutics, Inc. (TNYA), underscoring sustained analyst optimism. The TNYA analyst rating note cited program momentum and upcoming interim data as drivers for the call. Investors should note the firms reiterated coverage without issuing new price targets. The market showed modest movement after the notes, reflecting measured investor response to maintained positive views.